Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ABHD6 | Q9BV23 | 4/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | MERTK | Q12866 | 5/20 | 0.38 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.38 |
| ▸ | AXL | P30530 | 2/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4183920 | 0.76 | ESR1 (0.74) | ESR1ESR2PKMABHD6MERTK | |
| SCHEMBL2993408 | 0.76 | ESR1 (0.68) | ESR1ESR2PKMABHD6HDAC6 | |
| SCHEMBL2821470 | 0.75 | ESR1 (0.76) | ESR1ESR2PKMABHD6MERTK | |
| SCHEMBL585650 | 0.75 | ESR1 (0.72) | ESR1ESR2PKMABHD6HDAC6 | |
| SCHEMBL8266789 | 0.75 | ESR1 (0.72) | ESR1ESR2PKMABHD6HDAC6 | |
| SCHEMBL1641841 | 0.75 | ESR1 (0.72) | ESR1ESR2PKMABHD6HDAC6 | |
| SCHEMBL2616863 | 0.75 | ESR1 (0.72) | ESR1ESR2PKMABHD6HDAC6 | |
| SCHEMBL13259386 | 0.75 | ESR1 (0.72) | ESR1ESR2PKMABHD6HDAC6 | |
| SCHEMBL3865684 | 0.75 | ESR1 (0.72) | ESR1ESR2PKMABHD6MERTK | |
| SCHEMBL30411956 | 0.75 | ESR1 (0.72) | ESR1ESR2PKMABHD6HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023094828-A1 | ANTAGONISTS OF CAV 2.3 | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |